Astugenal

Astugenal is the brand name for Antineoplaston AS2-1, a synthetic formulation of amino acid derivatives developed by the Burzynski Research Institute. It is primarily investigated for the treatment of malignant brain tumors, such as anaplastic astrocytoma and glioblastoma. The drug is typically administered as an intravenous infusion, often in a regimen combined with Atengenal (Antineoplaston A10). According to the developer, these 'antineoplastons' function as biochemical messengers that can normalize cancer cells by modulating the expression of oncogenes and tumor suppressor genes, although this mechanism remains controversial and is not widely recognized in conventional oncology. Clinical development has focused on Phase II trials for recurrent or refractory primary brain tumors.

Brand names

Astugenal

Other names

Antineoplaston AS2-1